Whatman Specialty Products, Inc.
Cytiva is dedicated to advancing healthcare by providing innovative solutions and technologies in bioprocessing, diagnostics, and life sciences. They focus on accelerating the development and commercialization of diagnostic assays, supporting bioprocessing, and enabling cutting-edge research and therapeutics.
Industries
Nr. of Employees
Very Large (1000+)
Whatman Specialty Products, Inc.
100 Results Way, Marlborough, MA 01752, USA
Products
LNP reagent kits and RNA delivery kits
Pre-formulated LNP reagent kits and application-specific LNP kits to accelerate formulation screening and development of RNA therapeutics.
Cellulose dipstick pads (range of thickness and wicking properties)
A range of cellulose pad substrates with defined thickness, absorbency, wicking rate and wet-strength suitable for dipstick and dry-chemistry assays.
Prepacked ion exchange chromatography columns
Validated, quality-controlled ion exchange columns supplied prepacked to reduce packing variability and accelerate chromatography setup for protein purification.
Single-use bioreactor and mixing systems
Single-use stirred-tank bioreactor systems and single-use mixing platforms designed to support flexible batch sizes and scale-up workflows in biomanufacturing.
LNP reagent kits and RNA delivery kits
Pre-formulated LNP reagent kits and application-specific LNP kits to accelerate formulation screening and development of RNA therapeutics.
Cellulose dipstick pads (range of thickness and wicking properties)
A range of cellulose pad substrates with defined thickness, absorbency, wicking rate and wet-strength suitable for dipstick and dry-chemistry assays.
Prepacked ion exchange chromatography columns
Validated, quality-controlled ion exchange columns supplied prepacked to reduce packing variability and accelerate chromatography setup for protein purification.
Single-use bioreactor and mixing systems
Single-use stirred-tank bioreactor systems and single-use mixing platforms designed to support flexible batch sizes and scale-up workflows in biomanufacturing.
Services
Project-based services from component customization and prototyping to full assay development and commercialization support for immunoassays and molecular assays.
Contract services including conjugation, lyophilization, and manufacturing to support scale up and production of diagnostic reagents and components.
Kits, reagents and formulation support for screening, optimizing and scaling lipid nanoparticle formulations for RNA therapeutics and vaccines.
Label-free interaction analysis and analytical troubleshooting to validate reagent selection and assay performance.
Field application specialist support, preventive maintenance and connected equipment services to maintain instrument uptime and performance.
Project-based services from component customization and prototyping to full assay development and commercialization support for immunoassays and molecular assays.
Contract services including conjugation, lyophilization, and manufacturing to support scale up and production of diagnostic reagents and components.
Kits, reagents and formulation support for screening, optimizing and scaling lipid nanoparticle formulations for RNA therapeutics and vaccines.
Label-free interaction analysis and analytical troubleshooting to validate reagent selection and assay performance.
Field application specialist support, preventive maintenance and connected equipment services to maintain instrument uptime and performance.
Expertise Areas
- Lateral-flow and point-of-care immunoassay development
- Dipstick colorimetric assay development
- Molecular point-of-care assay adaptation
- Nanomedicine and LNP formulation development
Key Technologies
- Lateral-flow assays (LFAs)
- Dipstick colorimetric assays
- Nitrocellulose membranes
- Cellulose and glass-fiber substrates
News & Updates
Strategic investments across Asia-Pacific, Europe and the US to support long-term growth and regional manufacturing strategies.
Expansion of bioreactor options to help advance the discovery of next-generation therapeutics.
A study using VIA Extractor™ tissue disaggregator paired with HIVE™ scRNAseq.
Reinforcing commitment to sustainability with ACT labeling.
Investments totaling 1.6 billion USD to enhance supply chain resilience and customer benefits.
Addition of 500L and 2,000L bioreactors to support advanced therapeutics discovery.
Strategic investments across Asia-Pacific, Europe and the US to support long-term growth and regional manufacturing strategies.
Expansion of bioreactor options to help advance the discovery of next-generation therapeutics.
A study using VIA Extractor™ tissue disaggregator paired with HIVE™ scRNAseq.
Reinforcing commitment to sustainability with ACT labeling.
Investments totaling 1.6 billion USD to enhance supply chain resilience and customer benefits.
Addition of 500L and 2,000L bioreactors to support advanced therapeutics discovery.